Rakuten Medical Announces FDA Acceptance Of An Investigational New Drug (IND) Application For RM-1995, A Conjugate Of IR700 And Anti-CD25 Antibody

By PR Newswire SAN DIEGO, Dec. 15, 2021 /PRNewswire/ — Rakuten Medical, Inc today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application to begin clinical studies of RM-1995 photoimmunotherapy in patients with advanced cutaneous squamous cell carcinoma or with head and neck squamous cell carcinoma. RM-1995 photoimmunotherapy treatment is an investigational drug-device combination being developed by Rakuten Medical, Inc. The drug portion of the treatment, RM-1995, is a conjugate of a photoactivatable dye (IRDye® 700DX [I…

Read More